Cafepharma Today

June 6 2025 - Novartis presses court for hasty decision in long-running Entresto patent feud with MSN
Novartis presses court for hasty decision in long-running Entresto patent feud with MSN
'Not a horse and pony show': At FDA cell and gene roundtable, officials look for ways to cut red tape
With ADCs on the rise, drugmakers embrace a new oncology pillar
Bayer trial combines two top drugs for kidney disease
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Why Novartis Is One of Today's Most Innovative Companies
Motley Fool
Saturday, February 15, 2014 - 11:24am
tags:
Novartis
Amarin Corporation Plc's Rocky Road
Motley Fool
Saturday, February 15, 2014 - 11:23am
tags:
Amarin
Why the FDA Still Won’t Approve J&J’s Blood Clot Medicine
Wall St Cheat Sheet
Saturday, February 15, 2014 - 11:12am
tags:
FDA, JNJ, Xarelto, anti-clotting
Mylan unit issues voluntary recall of 10 lots of Etomidate Injection
The Fly on the Wall
Saturday, February 15, 2014 - 11:10am
tags:
Mylan, recalls
Arena Prescriptions Tracking With Expectations
Seeking Alpha
Saturday, February 15, 2014 - 11:03am
tags:
Arena Pharmaceuticals, Belviq, obesity, weight loss
Celgene Plans Stock Split
Yahoo/Zacks
Saturday, February 15, 2014 - 11:01am
tags:
Celgene
Drug Quality Concerns Spur New U.S. FDA Oversight Effort
Bloomberg
Friday, February 14, 2014 - 6:36pm
tags:
FDA, India, generics, drug manufacturing
Echo Therapeutics Facing Major Execution Risks In A Very Competitive Market
Seeking Alpha
Friday, February 14, 2014 - 6:34pm
tags:
Echo Therapeutics, blood glucose monitoring, devices, diabetes
AstraZeneca's Crestor gets FDA orphan designation
Yahoo/Fly on the Wall
Friday, February 14, 2014 - 6:31pm
tags:
AstraZeneca, FDA, orphan drugs, Crestor, pediatric homozygous familial hypercholesterolemia
FDA approves BioMarin's genetic disorder drug Vimizim
Yahoo/Reuters
Friday, February 14, 2014 - 6:29pm
tags:
Biomarin, FDA, Vimizim, Morquio A Syndrome
Biotech IPOs: Class of 2014 still rolling as investors line up to cash in
Fierce Biotech
Friday, February 14, 2014 - 1:09pm
tags:
biotech, IPOs, Dicerna Pharmaceuticals, Ultragenyx, Auspex, GlycoMimetics, Revance Therapeutics
GlaxoSmithKline eyes rare disease to widen its respiratory lead
Fierce Biotech
Friday, February 14, 2014 - 1:07pm
tags:
GSK, mepolizumab, EGPA
Deals Of The Week: UCSF Catalyzes R&D Tech-Transfer Deals With Private Sector
In Vivo Blog
Friday, February 14, 2014 - 1:06pm
tags:
MedImmune, AstraZeneca, UCSF Medical Center, R&D
Medtronic looks to overturn $393M heart valve loss to Edwards Lifesciences
Mass Device
Friday, February 14, 2014 - 1:04pm
tags:
Medtronic, heart valve, Edwards Lifesciences, devices
NPS, Iroko show how companies can grow sales, not staff
Fierce Pharma
Friday, February 14, 2014 - 1:01pm
tags:
NPS Pharmaceuticals, Iroko Pharmaceuticals, Zorvolex, Gattex
Gilead says payers feel comfortable with the cost of Sovaldi
Fierce Pharma
Friday, February 14, 2014 - 12:59pm
tags:
Gilead, Sovaldi, insurance, hepatitis C
Demon Disease Targeted by AstraZeneca as Gout Rates Soar
Bloomberg
Friday, February 14, 2014 - 12:58pm
tags:
gout, AstraZeneca, lesinurad
Can Pfizer Crush the Market in 2014?
Motley Fool
Friday, February 14, 2014 - 12:54pm
tags:
Pfizer, palbociclib, breast cancer, vaccines, Prevnar
AstraZeneca’s Alzheimer’s Drug Advances: Now What?
Motley Fool
Friday, February 14, 2014 - 12:51pm
tags:
AstraZeneca, Alzheimer's disease, AZD3293
Alnylam Widens Q4 Loss
Yahoo/Zacks.com
Friday, February 14, 2014 - 12:46pm
tags:
Alnylam, earnings

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Cleaning Up the Medical Literature
In the Pipeline
Not One of Your Easy Crystals
In the Pipeline
The Continuing Crisis, Part XV: The Horrendous Trump Budget
In the Pipeline
Taurine Revisited
In the Pipeline
A New Route to Asthma Treatment - Through the Liver, of All Places
In the Pipeline
One Drug's Supply Chain, In Detail
In the Pipeline
A Reaction to Alzheimer's Fraud
In the Pipeline
Whoa Now: Cautionary Tales from Materials Science
In the Pipeline
Inside a Scientific Paper Mill
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.